Rabinovich et al. studied anti-VEGF refractory tumors and found that glycans on the endothelial surface glycoproteins, including VEGFR2, were remodeled to selectively bind galectin-1 (Gal-1) expressed by the tumor cells. Here, LGALS1 is linked to neoplasm.